Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(99)
•••
Comment by Aarcoron Feb 17, 2017 10:50am
175 Views
Post# 25860884

RE:RE:RE:reality check

RE:RE:RE:reality checkLots of hand wringing here.

I'm surprised there has been no dialogue around the tailwinds licensing report posted on their blog. Unless it's completely wrong, and the silence on the board has me concerned about that, it implies positive and interesting things around cash flow in the next 6 months - like Bioasis management is waiting for that flow to materialize and then they use that money to advance internal programs.  Seems like the major aim of their business plan is focused on 2019 and Herceptin patent expiration.  I complained it wasn't moving fast enough in 2015, but if the goal is a wholly-owned conjugate in 2019 I'm happy with that.

Having said all that, the stock just acts like one typically does when a financing is imminent and already priced in.  But who cares about that other than shareholders who are way over-leveraged or looking for a relatively quick trade ?  If you're white-knuckling every tick, you're in too deep.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities